CRISPR/Cas9 in Cancer: Pioneering Gene Editing for Improved Drug Discovery

Cancer remains a challenging problem globally, with traditional drug discovery methods focusing on cytotoxic agents and targeted therapies changing the course of cancer prognosis and treatment. Despite these advances, long-term therapeutic responses remain difficult to achieve due to tumor heterogeneity and resistance to targeted therapies; this hinders dosage effectiveness, reduces treatment effectiveness, and affects overall clinical outcomes. This underscores the critical need for new therapeutic strategies that can effectively control and potentially reverse carcinogenesis.

This Research Topic focuses on CRISPR-Cas9, a breakthrough gene editing technology that is changing the cancer drug discovery landscape by enabling precise and effective manipulation of genetic targets. Through techniques such as gene knockout, knockout, and transcriptional modulation, CRISPR-Cas9 accelerates the development of cancer treatments by offering a direct approach to identify and validate new drug targets. As this technology advances, it is imperative to capture the latest discoveries, address current gaps, and discuss future directions in applying CRISPR-Cas9 for cancer drug discovery.

In order to enrich the discourse and scope of research in this field, we welcome applications that include, but are not limited to, the following topics:

• CRISPR/Cas9 methodologies in drug screening, including gene knockouts, knockouts, and transcriptional modifications.
• Applications of CRISPR-Cas9 in targeted delivery systems such as nanoparticles and peptide carriers for cancer therapy.
• The potential of CRISPR/Cas9 to innovate future drug development.
• Strategies using CRISPR/Cas9 to combat drug resistance in cancer.
• Using CRISPR/Cas9 libraries to identify new drug targets.
• CRISPR/Cas9 research in cancer immunotherapy and transgenic animal model development.
• Real-world applications of CRISPR/Cas9 in clinical trials and cancer drug validation.

Submissions may include Original Research, Reviews, Mini-reviews, Clinical Trial results, and Perspectives highlighting the impact and potential of CRISPR-Cas9 in next-generation cancer drug discovery. Contributions should seek to combine genomic editing capabilities with practical, clinical applications to create new avenues for cancer treatment.

Please note: manuscripts that consist solely of bioinformatics or computational analysis of publicly available genomic or transcriptomic databases and are not accompanied by validation (independent cohort or in vitro or in vivo biological validation) are outside the scope of this section and will not be considered as part of it. of this Research Topic.

Keywords: Cancer drug discovery, Drug sensitivity/Resistance, Cancer treatment, Gain of function/Loss of function, Immunotherapy, CRISPR/Cas9

Important Note: All contributions to this Research Topic must be within the scope of the department and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to refer an out-of-scope manuscript to a more appropriate section or journal at any stage of peer review.

Cancer remains a challenging problem globally, with traditional drug discovery methods focusing on cytotoxic agents and targeted therapies changing the course of cancer prognosis and treatment. Despite these advances, long-term therapeutic responses remain difficult to achieve due to tumor heterogeneity and resistance to targeted therapies; this hinders dosage effectiveness, reduces treatment effectiveness, and affects overall clinical outcomes. This underscores the critical need for new therapeutic strategies that can effectively control and potentially reverse carcinogenesis.

This Research Topic focuses on CRISPR-Cas9, a breakthrough gene editing technology that is changing the cancer drug discovery landscape by enabling precise and effective manipulation of genetic targets. Through techniques such as gene knockout, knockout, and transcriptional modulation, CRISPR-Cas9 accelerates the development of cancer treatments by offering a direct approach to identify and validate new drug targets. As this technology advances, it is imperative to capture the latest discoveries, address current gaps, and discuss future directions in applying CRISPR-Cas9 for cancer drug discovery.

In order to enrich the discourse and scope of research in this field, we welcome applications that include, but are not limited to, the following topics:

• CRISPR/Cas9 methodologies in drug screening, including gene knockouts, knockouts, and transcription modifications.
• Applications of CRISPR-Cas9 in targeted delivery systems such as nanoparticles and peptide carriers for cancer therapy.
• The potential of CRISPR/Cas9 to innovate future drug development.
• Strategies using CRISPR/Cas9 to combat drug resistance in cancer.
• Using CRISPR/Cas9 libraries to identify new drug targets.
• CRISPR/Cas9 research in cancer immunotherapy and transgenic animal model development.
• Real-world applications of CRISPR/Cas9 in clinical trials and cancer drug validation.

Submissions may include Original Research, Reviews, Mini-reviews, Clinical Trial results, and Perspectives highlighting the impact and potential of CRISPR-Cas9 in next-generation cancer drug discovery. Contributions should seek to combine genomic editing capabilities with practical, clinical applications to create new avenues for cancer treatment.

Please note: manuscripts that consist solely of bioinformatics or computational analysis of publicly available genomic or transcriptomic databases and are not accompanied by validation (independent cohort or in vitro or in vivo biological validation) are outside the scope of this section and will not be considered as part of it. of this Research Topic.

Keywords: Cancer drug discovery, Drug sensitivity/Resistance, Cancer treatment, Gain of function/Loss of function, Immunotherapy, CRISPR/Cas9

Important Note: All contributions to this Research Topic must be within the scope of the department and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to refer an out-of-scope manuscript to a more appropriate section or journal at any stage of peer review.